Advertisement

Topics

Tecentriq Approved for Metastatic Non-Small Cell Lung Cancer

16:03 EDT 18 Oct 2016 | Medscape

The FDA approved the immunotherapy drug, a PD-L1 inhibitor, for patients with metastatic NSCLC who have progressed after platinum-based chemotherapy and targeted therapy, if appropriate.
FDA Approvals

Original Article: Tecentriq Approved for Metastatic Non-Small Cell Lung Cancer

NEXT ARTICLE

More From BioPortfolio on "Tecentriq Approved for Metastatic Non-Small Cell Lung Cancer"

Quick Search
Advertisement
 

Relevant Topics

Biological Therapy
Biological therapy involves the use of living organisms, substances derived from living organisms, or laboratory-produced versions of such substances to treat disease. Some biological therapies for cancer use vaccines or bacteria to stimulate the body&rs...

Pharmacy
Pharmacy is the science and technique of preparing as well as dispensing drugs and medicines. It is a health profession that links health sciences with chemical sciences and aims to ensure the safe and effective use of pharmaceutical drugs. The scope of...